Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

0.8885 -0.0415 (-4.46%)
Streaming Delayed Price Updated: 2:38 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
From DJS Law Group
Via Business Wire
News headline image
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results ↗
ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates. 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; Tesla Shares Spike Higher ↗
 
Via Benzinga
Why Is aTyr Stock Falling Today? ↗
Via Stocktwits
News headline image
New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Atyr Pharma Stock Slipping Premarket? ↗
Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point. 
Via Stocktwits
News headline image
1 Small-Cap Biotech Stock Poised for a Breakout ↗
The next couple of weeks could reveal a great deal about this stock's prospects. 
Via The Motley Fool
News headline image
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
5 Biotech Stocks with Highly Anticipated Pending Results ↗
Via Stocktwits
Topics Intellectual Property
News headline image
These stocks that are showing activity before the opening bell on Friday. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
What's going on in today's after hours session ↗
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications. 
From aTyr Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.